Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04630002 · ClinicalTrials.gov registry record · Phase 1
Drug-drug Interaction (DDI) Study of GSK3640254 With Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR)
A Phase 1 study, sponsored by ViiV Healthcare.
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
NCT04630002 is a Phase 1 study that has completed, run by ViiV Healthcare. The registered enrollment target is 54 participants.
The verdict
NCT04630002, a Phase 1 study, has completed, sponsored by ViiV Healthcare.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
Study Summary
This is an open-label, single-sequence, multiple-dose, 3 cohort study to investigate the effects of DRV/RTV and/or ETR on the pharmacokinetics (PK) of GSK3640254 and the effects of GSK3640254 on the PK of DRV/RTV and/or ETR. This study will aid in understanding these interactions and resulting changes in exposure (if any) when given in combination with GSK3640254.
Interventions
- DRUG GSK3640254
- DRUG Etravirine (ETR)
- DRUG Darunavir/Ritonavir (DRV/RTV)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2020-10-28 |
| Est. Completion | 2021-10-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04630002
The ClinicalTrials.gov registry entry for NCT04630002 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which GSK3640254 is the first listed.
NCT04630002 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04630002 about?
NCT04630002 is a clinical study titled "Drug-drug Interaction (DDI) Study of GSK3640254 With Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR)". This is an open-label, single-sequence, multiple-dose, 3 cohort study to investigate the effects of DRV/RTV and/or ETR on the pharmacokinetics (PK) of GSK3640254 and the effects of GSK3640254 on the PK of DRV/RTV and/or ETR. This study will aid in understanding these interactions and resulting chang...
What is the current status of trial NCT04630002?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2020-10-28. Estimated completion is 2021-10-02.
What interventions are being tested in trial NCT04630002?
The interventions under investigation include: GSK3640254 (DRUG), Etravirine (ETR) (DRUG), Darunavir/Ritonavir (DRV/RTV) (DRUG).
Who is sponsoring clinical trial NCT04630002?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.